<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477594</url>
  </required_header>
  <id_info>
    <org_study_id>301012-CS17</org_study_id>
    <secondary_id>2007-001024-12</secondary_id>
    <nct_id>NCT00477594</nct_id>
  </id_info>
  <brief_title>Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia</brief_title>
  <official_title>An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of extended dosing of
      mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have
      completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug
      trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial Hypercholesterolemia (FH) is an autosomal dominant metabolic disorder characterized
      by markedly elevated low density lipoprotein (LDL), premature onset of atherosclerosis, and
      development of xanthomata. There are two distinct subpopulations that have a high unmet
      medical need due to the lack of alternative therapy: homozygotes, who have two defective LDL
      receptor (LDL-R) genes, and heterozygotes with a history of cardiovascular disease (CVD) on
      maximally tolerated therapy. Treatment for FH is directed at lowering plasma levels of LDL-C.

      Mipomersen is an antisense drug targeted to human apolipoprotein B (apoB), the principal
      apolipoprotein of atherogenic LDL-C and its metabolic precursor, very low density lipoprotein
      (VLDL). Mipomersen is complimentary to the coding region of the messenger ribonucleic acid
      (mRNA) for apo-B. Inhibition of apo-B would be expected to impair VLDL synthesis and result
      in lowered levels of LDL-C.

      In early clinical trials, mipomersen has been shown to reduce levels of LDL-C to recommended
      target levels in some participants.

      This was an open-label extension study, which consisted of a ≤2-week screening period, up to
      3 years of treatment with mipomersen, and a 24-week post-treatment follow-up period. Patients
      who participated in Cohorts A, B, or C in study 301012-CS9 were randomized in a 1:1 ratio to
      mipomersen 200 mg once a week (QW) or 200 mg mipomersen every other week (QOW) for up to 3
      years. Patients randomized to mipomersen 200 mg QOW were allowed to receive mipomersen 200 mg
      QW at the Investigator's discretion after the first 52 weeks of the treatment period.
      Patients who participated in study 301012-CS8 or Cohort D of study 301012-CS9 received 200 mg
      mipomersen QW for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides &lt;400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density Lipoprotein Cholesterol (LDL-C) Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Samples were taken following an overnight fast. For patients with triglycerides &lt;400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B</measure>
    <time_frame>Baseline and Weeks 52 and 104</time_frame>
    <description>Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-High-Density Lipoprotein Cholesterol Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>2 years</time_frame>
    <description>AEs were considered as related if assessed by the Investigator as possibly, probably or definitely related to study drug. The severity of each event was assessed using the following categories: Mild (symptom(s) barely noticeable to the patient or do not make the patient uncomfortable); Moderate (symptom(s) of a sufficient severity to make the patient uncomfortable, performance of daily activities is influenced) or Severe (symptom(s) of a sufficient severity to cause the patient severe discomfort, may cause cessation of treatment with the study drug). Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Clinical Chemistry Parameters</measure>
    <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Hematology Parameters</measure>
    <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Respiratory Rate</measure>
    <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Triglycerides</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Triglycerides were measured in mg/dL. Samples were taken following an overnight fast.</description>
  </other_outcome>
  <other_outcome>
    <measure>Triglycerides Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Lipoprotein(a)</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Lipoprotein(a) was measured in mg/dL. Samples were taken following an overnight fast.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipoprotein(a) Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Very-Low-Density Lipoprotein (VLDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
  </other_outcome>
  <other_outcome>
    <measure>Very-Low-Density Lipoprotein (VLDL) Cholesterol Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A1</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>Apolipoprotein A1 was measured in mg/dL. Samples were taken following an overnight fast.</description>
  </other_outcome>
  <other_outcome>
    <measure>Apolipoprotein A1 Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>High-Density Lipoprotein (HDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
  </other_outcome>
  <other_outcome>
    <measure>High-Density Lipoprotein Cholesterol Over Time</measure>
    <time_frame>Baseline and Weeks 52 and 104.</time_frame>
    <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Lipid Metabolism, Inborn Errors</condition>
  <condition>Hypercholesterolemia, Autosomal Dominant</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Hyperlipoproteinemia Type II</condition>
  <condition>Metabolism, Inborn Errors</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Infant, Newborn, Diseases</condition>
  <condition>Metabolic Disorder</condition>
  <condition>Congenital Abnormalities</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipoproteinemias</condition>
  <condition>Dyslipidemias</condition>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Mipomersen 200 mg per week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mipomersen 200 mg every other week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mipomersen sodium</intervention_name>
    <description>200 mg/ml, in 1 ml solution for subcutaneous injection.</description>
    <arm_group_label>Mipomersen 200 mg per week</arm_group_label>
    <arm_group_label>Mipomersen 200 mg every other week</arm_group_label>
    <other_name>ISIS 301012</other_name>
    <other_name>Kynamro™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Satisfactory completion of dosing and Week 7 or Week 15 assessments (depending on the
        treatment and dose received) in their initial study (Protocol 301012-CS8 (NCT00280995) or
        301012-CS9 (NCT00281008)).

        Exclusion Criteria:

        - Have a new condition or worsening of existing condition which in the opinion of the
        Investigator would make the patient unsuitable for enrollment, or could interfere with
        patient's participation in or completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>February 25, 2013</results_first_submitted>
  <results_first_submitted_qc>February 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2013</results_first_posted>
  <disposition_first_submitted>January 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 23, 2012</disposition_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Hypercholesterolemia</keyword>
  <keyword>Heterozygous Familial Hypercholesterolemia</keyword>
  <keyword>Homozygous Familial Hypercholesterolemia</keyword>
  <keyword>ISIS 301012</keyword>
  <keyword>mipomersen</keyword>
  <keyword>Open Label Extension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who completed dosing in study 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) at a site in the U.S. with an acceptable safety profile, per Investigator judgment, were eligible to enroll in this study.</recruitment_details>
      <pre_assignment_details>Patients who participated in Cohorts A, B, or C in study 301012-CS9 were randomized in a 1:1 ratio to mipomersen 200 mg once a week (QW) or 200 mg mipomersen every other week (QOW). Patients who participated in study 301012-CS8 or Cohort D of study 301012-CS9 received 200 mg mipomersen QW.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mipomersen 200 mg Per Week</title>
          <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
        </group>
        <group group_id="P2">
          <title>Mipomersen 200 mg Every Other Week</title>
          <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1 and Year 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mipomersen 200 mg Per Week</title>
          <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
        </group>
        <group group_id="B2">
          <title>Mipomersen 200 mg Every Other Week</title>
          <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="11.6"/>
                    <measurement group_id="B2" value="54.6" spread="15.7"/>
                    <measurement group_id="B3" value="48.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="5.60"/>
                    <measurement group_id="B2" value="27.4" spread="4.81"/>
                    <measurement group_id="B3" value="28.6" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolic syndrome</title>
          <description>A patient was classified as having metabolic syndrome if any 3 of the following risk factors existed: 1) Waist circumference ≥102 cm (men) or ≥88 cm (women); 2) Triglycerides ≥150 mg/dL*; 3) High density lipoprotein cholesterol &lt;40 mg/dL (men) or &lt;50 mg/dL (women)*; 4) Systolic blood pressure ≥130 or diastolic ≥85 mmHg*; 5) Fasting glucose ≥100 mg/dL*.
* = or on medication for the specified risk factor.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides &lt;400 mg/dL, LDL-C was obtained using Friedewald’s calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <description>LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides &lt;400 mg/dL, LDL-C was obtained using Friedewald’s calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" lower_limit="-41.8" upper_limit="-7.8"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-10.2" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" lower_limit="-38.8" upper_limit="-16.6"/>
                    <measurement group_id="O2" value="30.6" lower_limit="30.6" upper_limit="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" lower_limit="-31.4" upper_limit="-3.0"/>
                    <measurement group_id="O2" value="9.5" lower_limit="3.4" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Low-density Lipoprotein Cholesterol (LDL-C) Over Time</title>
        <description>Samples were taken following an overnight fast. For patients with triglycerides &lt;400 mg/dL, LDL-C was obtained using Friedewald’s calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Low-density Lipoprotein Cholesterol (LDL-C) Over Time</title>
          <description>Samples were taken following an overnight fast. For patients with triglycerides &lt;400 mg/dL, LDL-C was obtained using Friedewald’s calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177" lower_limit="134" upper_limit="205"/>
                    <measurement group_id="O2" value="131" lower_limit="124" upper_limit="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" lower_limit="106" upper_limit="173"/>
                    <measurement group_id="O2" value="127" lower_limit="124" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="82" upper_limit="156"/>
                    <measurement group_id="O2" value="162" lower_limit="162" upper_limit="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5}</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="116" upper_limit="213"/>
                    <measurement group_id="O2" value="161" lower_limit="146" upper_limit="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B</title>
        <description>Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B</title>
          <description>Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" lower_limit="-39.1" upper_limit="-11.0"/>
                    <measurement group_id="O2" value="-7.3" lower_limit="-19.7" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" lower_limit="-39.7" upper_limit="-22.4"/>
                    <measurement group_id="O2" value="20.8" lower_limit="20.8" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" lower_limit="-26.2" upper_limit="-3.5"/>
                    <measurement group_id="O2" value="-3.7" lower_limit="-14.9" upper_limit="-1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" lower_limit="127" upper_limit="181"/>
                    <measurement group_id="O2" value="124" lower_limit="109" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" lower_limit="102" upper_limit="146"/>
                    <measurement group_id="O2" value="110" lower_limit="104" upper_limit="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" lower_limit="73" upper_limit="146"/>
                    <measurement group_id="O2" value="128" lower_limit="128" upper_limit="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="104" upper_limit="175"/>
                    <measurement group_id="O2" value="128" lower_limit="122" upper_limit="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol</title>
        <description>Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol</title>
          <description>Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" lower_limit="-26.8" upper_limit="-6.4"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-13.4" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.3" lower_limit="-29.2" upper_limit="-18.0"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-1.5" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" lower_limit="-24.2" upper_limit="-2.4"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-1.7" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251" lower_limit="206" upper_limit="293"/>
                    <measurement group_id="O2" value="233" lower_limit="199" upper_limit="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" lower_limit="173" upper_limit="245"/>
                    <measurement group_id="O2" value="203" lower_limit="192" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="143" upper_limit="209"/>
                    <measurement group_id="O2" value="196" lower_limit="196" upper_limit="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="193" upper_limit="297"/>
                    <measurement group_id="O2" value="231" lower_limit="199" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol</title>
        <description>Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol</title>
          <description>Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" lower_limit="-40.5" upper_limit="-12.6"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-15.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" lower_limit="-37.9" upper_limit="-21.6"/>
                    <measurement group_id="O2" value="17.2" lower_limit="17.2" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" lower_limit="-31.2" upper_limit="-6.6"/>
                    <measurement group_id="O2" value="3.7" lower_limit="-3.0" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-High-Density Lipoprotein Cholesterol Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" lower_limit="167" upper_limit="253"/>
                    <measurement group_id="O2" value="151" lower_limit="149" upper_limit="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="134" upper_limit="208"/>
                    <measurement group_id="O2" value="150" lower_limit="140" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" lower_limit="95" upper_limit="174"/>
                    <measurement group_id="O2" value="177" lower_limit="177" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" lower_limit="151" upper_limit="255"/>
                    <measurement group_id="O2" value="177" lower_limit="170" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs)</title>
        <description>AEs were considered as related if assessed by the Investigator as possibly, probably or definitely related to study drug. The severity of each event was assessed using the following categories: Mild (symptom(s) barely noticeable to the patient or do not make the patient uncomfortable); Moderate (symptom(s) of a sufficient severity to make the patient uncomfortable, performance of daily activities is influenced) or Severe (symptom(s) of a sufficient severity to cause the patient severe discomfort, may cause cessation of treatment with the study drug). Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>2 years</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs)</title>
          <description>AEs were considered as related if assessed by the Investigator as possibly, probably or definitely related to study drug. The severity of each event was assessed using the following categories: Mild (symptom(s) barely noticeable to the patient or do not make the patient uncomfortable); Moderate (symptom(s) of a sufficient severity to make the patient uncomfortable, performance of daily activities is influenced) or Severe (symptom(s) of a sufficient severity to cause the patient severe discomfort, may cause cessation of treatment with the study drug). Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>Safety set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Clinical Chemistry Parameters</title>
        <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Clinical Chemistry Parameters</title>
          <population>Safety set.</population>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase (ALT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.73" spread="112.98"/>
                    <measurement group_id="O2" value="29.96" spread="80.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.73" spread="86.00"/>
                    <measurement group_id="O2" value="3.53" spread="39.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, Indirect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.81" spread="20.56"/>
                    <measurement group_id="O2" value="12.50" spread="29.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.79" spread="57.97"/>
                    <measurement group_id="O2" value="0.48" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (BUN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="22.90"/>
                    <measurement group_id="O2" value="-11.06" spread="16.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.24" spread="36.85"/>
                    <measurement group_id="O2" value="40.95" spread="149.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.94" spread="12.54"/>
                    <measurement group_id="O2" value="-9.84" spread="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glomerular Filtration Rate (GFR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.20" spread="24.56"/>
                    <measurement group_id="O2" value="15.49" spread="21.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Hematology Parameters</title>
        <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Hematology Parameters</title>
          <population>Safety set</population>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="8.69"/>
                    <measurement group_id="O2" value="-5.24" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="7.61"/>
                    <measurement group_id="O2" value="-4.24" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="31.95"/>
                    <measurement group_id="O2" value="-5.99" spread="43.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.55" spread="11.88"/>
                    <measurement group_id="O2" value="-1.36" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Blood Pressure</title>
        <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Blood Pressure</title>
          <population>Safety set</population>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.99" spread="12.33"/>
                    <measurement group_id="O2" value="2.35" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="11.31"/>
                    <measurement group_id="O2" value="10.67" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Pulse Rate</title>
        <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Pulse Rate</title>
          <population>Safety set</population>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" spread="14.41"/>
                    <measurement group_id="O2" value="6.28" spread="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Respiratory Rate</title>
        <time_frame>Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Respiratory Rate</title>
          <population>Safety set</population>
          <units>percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="10.57"/>
                    <measurement group_id="O2" value="-4.44" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Triglycerides</title>
        <description>Triglycerides were measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides</title>
          <description>Triglycerides were measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" lower_limit="-36.3" upper_limit="-26.7"/>
                    <measurement group_id="O2" value="-27.0" lower_limit="-43.0" upper_limit="-3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.8" lower_limit="-58.2" upper_limit="-30.2"/>
                    <measurement group_id="O2" value="-44.8" lower_limit="-44.8" upper_limit="-44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" lower_limit="-42.9" upper_limit="2.2"/>
                    <measurement group_id="O2" value="-34.7" lower_limit="-36.1" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Triglycerides Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="96" upper_limit="254"/>
                    <measurement group_id="O2" value="134" lower_limit="92" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="67" upper_limit="150"/>
                    <measurement group_id="O2" value="90" lower_limit="80" upper_limit="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="67" upper_limit="113"/>
                    <measurement group_id="O2" value="74" lower_limit="74" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="76" upper_limit="180"/>
                    <measurement group_id="O2" value="122" lower_limit="97" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Lipoprotein(a)</title>
        <description>Lipoprotein(a) was measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein(a)</title>
          <description>Lipoprotein(a) was measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.2" lower_limit="-34.3" upper_limit="-4.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-27.3" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.7" lower_limit="-32.7" upper_limit="-24.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" lower_limit="-31.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-20.0" lower_limit="-25.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Lipoprotein(a) Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Lipoprotein(a) Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="15" upper_limit="98"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="23" upper_limit="75"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="33" upper_limit="79"/>
                    <measurement group_id="O2" value="3" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="24" upper_limit="71"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol</title>
        <description>Very-Low-Density Lipoprotein (VLDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol</title>
          <description>Very-Low-Density Lipoprotein (VLDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.6" lower_limit="-37.1" upper_limit="-25.0"/>
                    <measurement group_id="O2" value="-25.9" lower_limit="-43.6" upper_limit="-2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.6" lower_limit="-58.3" upper_limit="-31.6"/>
                    <measurement group_id="O2" value="-44.4" lower_limit="-44.4" upper_limit="-44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.0" lower_limit="-44.0" upper_limit="2.8"/>
                    <measurement group_id="O2" value="-35.0" lower_limit="-35.7" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Very-Low-Density Lipoprotein (VLDL) Cholesterol Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Very-Low-Density Lipoprotein (VLDL) Cholesterol Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="19" upper_limit="51"/>
                    <measurement group_id="O2" value="27" lower_limit="18" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="13" upper_limit="30"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O2" value="15" lower_limit="15" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="36"/>
                    <measurement group_id="O2" value="24" lower_limit="19" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol</title>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol</title>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" lower_limit="-43.6" upper_limit="-25.8"/>
                    <measurement group_id="O2" value="2.6" lower_limit="-11.8" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.2" lower_limit="-57.8" upper_limit="-34.6"/>
                    <measurement group_id="O2" value="230.1" lower_limit="230.1" upper_limit="230.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" lower_limit="-38.2" upper_limit="-18.5"/>
                    <measurement group_id="O2" value="15.2" lower_limit="3.1" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="9" lower_limit="9" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apolipoprotein A1</title>
        <description>Apolipoprotein A1 was measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein A1</title>
          <description>Apolipoprotein A1 was measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="-4.3" upper_limit="11.2"/>
                    <measurement group_id="O2" value="7.4" lower_limit="-5.3" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="-2.7" upper_limit="7.6"/>
                    <measurement group_id="O2" value="-55.1" lower_limit="-55.1" upper_limit="-55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="-0.7" upper_limit="9.5"/>
                    <measurement group_id="O2" value="-7.9" lower_limit="-11.8" upper_limit="-3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apolipoprotein A1 Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A1 Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="120" upper_limit="149"/>
                    <measurement group_id="O2" value="149" lower_limit="147" upper_limit="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" lower_limit="123" upper_limit="160"/>
                    <measurement group_id="O2" value="159" lower_limit="144" upper_limit="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="113" upper_limit="155"/>
                    <measurement group_id="O2" value="66" lower_limit="66" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" lower_limit="129" upper_limit="153"/>
                    <measurement group_id="O2" value="144" lower_limit="126" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol</title>
        <description>High-Density Lipoprotein (HDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol</title>
          <description>High-Density Lipoprotein (HDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>percentage of baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="6.4" upper_limit="32.4"/>
                    <measurement group_id="O2" value="6.8" lower_limit="-4.9" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="6.1" upper_limit="43.8"/>
                    <measurement group_id="O2" value="-60.4" lower_limit="-60.4" upper_limit="-60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="4.9" upper_limit="26.9"/>
                    <measurement group_id="O2" value="-17.9" lower_limit="-19.6" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>High-Density Lipoprotein Cholesterol Over Time</title>
        <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
        <time_frame>Baseline and Weeks 52 and 104.</time_frame>
        <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Mipomersen 200 mg Per Week</title>
            <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
          </group>
          <group group_id="O2">
            <title>Mipomersen 200 mg Every Other Week</title>
            <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>High-Density Lipoprotein Cholesterol Over Time</title>
          <description>For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.</description>
          <population>The Safety Set included all enrolled patients who received at least 1 injection of study drug. &quot;N&quot; indicates the number of participants with available data at the specified time point.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="33" upper_limit="46"/>
                    <measurement group_id="O2" value="52" lower_limit="48" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 [N=13, 4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="41" upper_limit="50"/>
                    <measurement group_id="O2" value="54" lower_limit="43" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 [N=7, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="35" upper_limit="48"/>
                    <measurement group_id="O2" value="19" lower_limit="19" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104/Early Termination [N=16, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="40" upper_limit="50"/>
                    <measurement group_id="O2" value="45" lower_limit="34" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years.</time_frame>
      <desc>In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mipomersen 200 mg Per Week</title>
          <description>Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.</description>
        </group>
        <group group_id="E2">
          <title>Mipomersen 200 mg Every Other Week</title>
          <description>Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator’s discretion after the first 52 weeks of the treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Arcus lipoides</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site coldness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Splinter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wrong technique in drug usage process</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Grief reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After the multicenter publication or 12 months after completion of the study the PI may publish the results of his/her data from the study. The PI shall provide the sponsor with an advance copy at least 60 days prior to planned submission and the Sponsor shall have 60 days to review (contracts have variable timeframes; maximum times are stated here). The sponsor may request the deletion of any confidential information, or a delay in submission for an additional period not to exceed 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Genzyme Medical Information</name_or_title>
      <organization>Genzyme Corporation</organization>
      <phone>617-252-7832</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

